Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Dipti Talaulikar^{1

2}, Douglas Joshua³, Phoebe Joy Ho^{3

4}, John Gibson^{3

4}, Hang Quach^{5

6}, Simon Gibbs^{7

8}, Silvia Ling⁹, Christopher Ward¹⁰, Bradley M Augustson¹¹, Judith Trotman^{4

12}, Simon J Harrison^{13

14}, Constantine S Tam^{6

15

16}; Medical and Scientific Advisory Group, Myeloma Australia

Affiliations

¹ ACT Pathology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
² College of Health and Medicine, Australian National University, Australian Capital Territory, Canberra, Australia.
³ Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁴ University of Sydney, Sydney, New South Wales, Australia.
⁵ St Vincent's Hospital, Melbourne, Victoria, Australia.
⁶ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
⁷ Department of Haematology, Eastern Health, Melbourne, Victoria, Australia.
⁸ Eastern Clinical Research Unit, Monash University, Melbourne, Victoria, Australia.
⁹ Liverpool Hospital, Sydney, New South Wales, Australia.
¹⁰ Royal North Shore Hospital, Sydney, New South Wales, Australia.
¹¹ Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
¹² Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
¹³ Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
¹⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia, Australia.
¹⁵ Alfred Hospital, Melbourne, Australia, Australia.
¹⁶ Central Clinical School, Monash University, Melbourne, Australia, Australia.

PMID: 36441109
DOI: 10.1111/imj.15980

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Dipti Talaulikar et al. Intern Med J. 2023 Apr.

. 2023 Apr;53(4):599-609.

doi: 10.1111/imj.15980. Epub 2023 Apr 5.

Authors

Affiliations

¹ ACT Pathology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
² College of Health and Medicine, Australian National University, Australian Capital Territory, Canberra, Australia.
³ Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁴ University of Sydney, Sydney, New South Wales, Australia.
⁵ St Vincent's Hospital, Melbourne, Victoria, Australia.
⁶ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
⁷ Department of Haematology, Eastern Health, Melbourne, Victoria, Australia.
⁸ Eastern Clinical Research Unit, Monash University, Melbourne, Victoria, Australia.
⁹ Liverpool Hospital, Sydney, New South Wales, Australia.
¹⁰ Royal North Shore Hospital, Sydney, New South Wales, Australia.
¹¹ Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
¹² Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
¹³ Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
¹⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia, Australia.
¹⁵ Alfred Hospital, Melbourne, Australia, Australia.
¹⁶ Central Clinical School, Monash University, Melbourne, Australia, Australia.

PMID: 36441109
DOI: 10.1111/imj.15980

Abstract

Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of IgM paraprotein, bone marrow infiltration by clonal small B lymphocytes with plasmacytic differentiation and the MYD88 L265P mutation in >90% of cases. Traditionally, WM has been treated with chemoimmunotherapy. Recent trials have demonstrated the efficacy and safety of Bruton tyrosine kinase inhibitors in WM, both as monotherapy and in combination with other drugs. There is emerging evidence on the use of other agents including B-cell lymphoma 2 inhibitors and on the treatment of rare presentations of WM. In this update, the Medical and Scientific Advisory Group of Myeloma Australia reviews the available evidence on the treatment of WM since the last publication in 2017 and provides specific recommendations to assist Australian clinicians in the management of this disease.

Keywords: Bruton tyrosine kinase inhibitor; Waldenström macroglobulinaemia; treatment.

PubMed Disclaimer

References

1. Swerdlow SHCE, Harris NL, Jaffe ES, Plieri SA, Stein H, Thiele J. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC; 2017.
1. Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H et al. Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J 2017; 47: 35-49.
1. Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Group, A, et al. Consensus clinical practice guidelines for the treatment of patients with Waldenström Macroglobulinaemia; 7 June 2022. Available from URL: https://myeloma.org.au/wp-content/uploads/2022/06/MSAG_waldenstro%CC%88m...
1. Maqbool MG, Tam CS, Morison IM, Simpson D, Mollee P, Schneider H et al. A practical guide to laboratory investigations at diagnosis and follow up in Waldenstrom macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology 2020; 52: 167-78.
1. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-10.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Affiliations

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Authors

Affiliations

Abstract

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical